Skip to main content
. Author manuscript; available in PMC: 2018 Oct 8.
Published in final edited form as: Thromb Res. 2018 Jul 6;169:96–104. doi: 10.1016/j.thromres.2018.07.003

Figure 1. Screening ARVs on platelet function in vitro reveals dysregulation by ritonavir.

Figure 1.

1.1×108/mL of washed human platelets were treated with the indicated antiretroviral drugs (ARVs) for 30 minutes with either 0.1% DMSO or PBS as vehicle. The following ARVs were tested at pharmacologically relevant concentrations: abacavir (ABC) 20 μM; ritonavir (RTV) 5 μM; tipranavir (TPV) 25 μM; atazanavir (ATV) 5 μM; darunavir (DAR) 5 μM; raltegravir (RAL) 20 μM; lamivudine (LAM) 20 μM. After treatment, platelet supernatant was analyzed for the lipid mediators A&C Prostaglandin E2 (PGE2), and B&D Thromboxane (TXB2). Statistics were determined with paired two-tailed T-tests. n≥3 *p<0.05. Symbols represent individual donors. Solid columns indicate the vehicle was DMSO, and gray dotted columns indicate vehicle was PBS.